Category: Tag:


INFLUVAC  is a a trivalent subunit influenza vaccine with its surface antigen inactivated.

This vaccine complies with the World Health Organisation (WHO) recommendation (Northern hemisphere) and EU recommendation for the 2016/2017 season.

Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains*:

-A/Michigan/45/2015 (H1N1)pdm09-like strain (A/Singapore/GP1908/2015, IVR-180) 15 micrograms HA **
-A/Hong Kong/4801/2014 (H3N2)-like strain (A/Hong Kong/4801/2014, X-263B) 15 micrograms HA **
-B/Brisbane/60/2008-like strain (B/Brisbane/60/2008, wild type) 15 micrograms HA **per 0.5 ml dose
*propagated in fertilised hens’eggs from healthy chicken flocks
** haemagglutiniN

Immunization Guideline

INFLUVAC is a subunit vaccine containing only viral surface antigens (or protein haemagglutinins). It is indicated for the prevention of influenza infection caused by the specific strains contained in the vaccine, in children above 6 months of age and adults. The recommended dose of INFLUVAC for children from 6 months to 35 months of age is 0.25 mL and children  from 3 years and  adults is 0.5 mL. If the child has not been previously vaccinated against flu, a second dose should be given after at least after 4 weeks.

Additional information






Ready to Use


1 Dose, 10 Dose


Intramuscular, Subcutaneous




INFLUVAC should not be given to people who have a hypersensitivity to the active substances, to any of the excipients or to any component that may be present as traces such as eggs, chicken protein (such as ovalbumin), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin. Immunization with INFLUVAC should be deferred in the presence of any acute illness, including acute or unstable neurologic illness, febrile illness, or active infection.